Rep. Jefferson Shreve Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares

Representative Jefferson Shreve (R-Indiana) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in Regeneron Pharmaceuticals stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

Regeneron Pharmaceuticals Price Performance

REGN traded down $1.40 during trading on Thursday, hitting $569.96. 253,630 shares of the company traded hands, compared to its average volume of 781,411. The company has a market cap of $62.31 billion, a PE ratio of 14.90, a P/E/G ratio of 2.34 and a beta of 0.43. The stock's 50-day simple moving average is $605.64 and its two-hundred day simple moving average is $689.30. Regeneron Pharmaceuticals, Inc. has a 1 year low of $520.50 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $9.55 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analyst Ratings Changes

Several research firms have recently commented on REGN. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Bank of America reduced their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Finally, TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $890.60.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Willner & Heller LLC raised its holdings in Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after purchasing an additional 15 shares during the last quarter. OLD Second National Bank of Aurora raised its holdings in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after purchasing an additional 15 shares during the last quarter. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after acquiring an additional 18 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.